Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (Oncogene, (2020), 39, 45, (6935-6949), 10.1038/s41388-020-01479-6)

Yezi Zhu, Susan L. Dalrymple, Ilsa Coleman, S. Lilly Zheng, Jianfeng Xu, Jody E. Hooper, Emmanuel S. Antonarakis, Angelo M. De Marzo, Alan K. Meeker, Peter S. Nelson, William B. Isaacs, Samuel R. Denmeade, Jun Luo, W. Nathaniel Brennen, John T. Isaacs

Research output: Contribution to journalComment/debatepeer-review

Abstract

Unfortunately, in the ESM of the original published version was the GEO accession number given incorrect. The accession number for the RNA-seq data for the PDXs with the mouse genes subtracted is NCBI GSE149433 and for the LNCaP-95 and AR-KO cells is NCBI GSE 131985. The original version was corrected.

Original languageEnglish (US)
Pages (from-to)2148
Number of pages1
JournalOncogene
Volume40
Issue number11
DOIs
StatePublished - Mar 18 2021

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (Oncogene, (2020), 39, 45, (6935-6949), 10.1038/s41388-020-01479-6)'. Together they form a unique fingerprint.

Cite this